Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes.

Schmidt LJ, Habacher W, Augustin T, Krahulec E, Semlitsch T.

Diabetes Obes Metab. 2014 Sep;16(9):769-79. doi: 10.1111/dom.12269. Epub 2014 Feb 24.

PMID:
24476092
[PubMed - in process]
2.

Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.

Li WX, Gou JF, Tian JH, Yan X, Yang L.

Curr Ther Res Clin Exp. 2010 Aug;71(4):211-38. doi: 10.1016/j.curtheres.2010.08.003. Review.

PMID:
24688145
[PubMed]
Free PMC Article
3.

Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.

Ahrén B, Gautier JF, Berria R, Stager W, Aronson R, Bailey CJ.

Diabetes Obes Metab. 2014 Sep;16(9):861-8. doi: 10.1111/dom.12290. Epub 2014 Apr 11.

PMID:
24641271
[PubMed - in process]
4.

Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.

Horowitz M, Rayner CK, Jones KL.

Adv Ther. 2013 Feb;30(2):81-101. doi: 10.1007/s12325-013-0009-4. Epub 2013 Feb 13. Review.

PMID:
23423907
[PubMed - indexed for MEDLINE]
5.

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.

Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Méry A.

Diabetes Obes Metab. 2013 Jul;15(7):642-9. doi: 10.1111/dom.12076. Epub 2013 Feb 25.

PMID:
23368510
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus.

Petersen AB, Christensen M.

Diabetes Metab Syndr Obes. 2013 Jun 17;6:217-31. doi: 10.2147/DMSO.S45379. Print 2013.

PMID:
23825925
[PubMed]
Free PMC Article
7.

Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: A randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).

Yu Pan C, Han P, Liu X, Yan S, Feng P, Zhou Z, Lv X, Tian H, Jin Kui Y, Su B, Shang S, Niemoeller E.

Diabetes Metab Res Rev. 2014 Mar 18. doi: 10.1002/dmrr.2541. [Epub ahead of print]

PMID:
24639432
[PubMed - as supplied by publisher]
8.

Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.

Bolli GB, Owens DR.

Diabetes Obes Metab. 2014 Jul;16(7):588-601. doi: 10.1111/dom.12253. Epub 2014 Jan 20.

PMID:
24373190
[PubMed - in process]
9.

Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.

Hanefeld M, Berria R, Lin J, Aronson R, Darmon P, Evans M, Van Gaal L.

Adv Ther. 2014 Aug;31(8):861-72. doi: 10.1007/s12325-014-0146-4. Epub 2014 Aug 21.

PMID:
25143188
[PubMed - in process]
10.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

PMID:
20646668
[PubMed - indexed for MEDLINE]
Free Article
11.

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).

Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 GetGoal-Mono Study Investigators.

Diabetes Care. 2012 Jun;35(6):1225-31. doi: 10.2337/dc11-1935. Epub 2012 Mar 19.

PMID:
22432104
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Lixisenatide for the treatment of type 2 diabetes.

Petersen AB, Knop FK, Christensen M.

Drugs Today (Barc). 2013 Sep;49(9):537-53. doi: 10.1358/dot.2013.49.9.2020940. Review.

PMID:
24086950
[PubMed - indexed for MEDLINE]
13.

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, Gerich JE.

Diabetes Care. 2013 Oct;36(10):2945-51. doi: 10.2337/dc12-2709. Epub 2013 May 22.

PMID:
23698396
[PubMed - indexed for MEDLINE]
14.

Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).

Rosenstock J, Hanefeld M, Shamanna P, Min KW, Boka G, Miossec P, Zhou T, Muehlen-Bartmer I, Ratner RE.

J Diabetes Complications. 2014 May-Jun;28(3):386-92. doi: 10.1016/j.jdiacomp.2014.01.012. Epub 2014 Jan 28.

PMID:
24650952
[PubMed - in process]
Free Article
15.

Glucagon-like peptide analogues for type 2 diabetes mellitus.

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD006423. doi: 10.1002/14651858.CD006423.pub2. Review.

PMID:
21975753
[PubMed - indexed for MEDLINE]
16.

The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.

Christensen M, Miossec P, Larsen BD, Werner U, Knop FK.

Expert Opin Drug Discov. 2014 Aug 14:1-29. [Epub ahead of print]

PMID:
25119443
[PubMed - as supplied by publisher]
17.

Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.

Seino Y, Takami A, Boka G, Niemoeller E, Raccah D; PDY6797 investigators.

Diabetes Obes Metab. 2014 Aug;16(8):739-47. doi: 10.1111/dom.12276. Epub 2014 Mar 12.

PMID:
24524806
[PubMed - in process]
18.

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

Pinelli NR, Hurren KM.

Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Review.

PMID:
21730278
[PubMed - indexed for MEDLINE]
19.

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators.

Diabetes Obes Metab. 2012 Oct;14(10):910-7. doi: 10.1111/j.1463-1326.2012.01618.x. Epub 2012 May 30.

PMID:
22564709
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Lixisenatide as add-on to oral antidiabetic therapy: an effective treatment for glycemic control with body weight benefits in type 2 diabetes.

Raccah D, Gourdy P, Sagnard L, Ceriello A.

Diabetes Metab Res Rev. 2014 Mar 28. doi: 10.1002/dmrr.2548. [Epub ahead of print]

PMID:
24687427
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk